Therefore, the leptin/ObR axis has been widely studied (44) as a target for an adjuvant therapy, not only in ER-positive tumor status (42), but also in triple-negative tumors (45), in which the lack of hormonal receptors reduces the therapeutic options. The gene discussed is LEP; the disease is neoplasm.